文献速递膀胱癌与上尿路尿路上皮癌

根治性膀胱切除术中加速康复外科方案的前瞻性实施

Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy.
PubMed 文献 · Eur Urol · 2017-08-08

该研究在前瞻性连续接受根治性膀胱切除术的患者中实施包含26项措施的加速康复外科(ERAS)方案,主要结局为住院时间和再入院率。结果显示ERAS组住院时间、术中失血量、输血率和再入院率均低于非ERAS组,而组织病理学参数和生存结局无差异;多因素分析显示ERAS使用与住院时间独立相关。作者结论认为ERAS可加快康复且不增加再入院或改变肿瘤学结局,应鼓励采用。

要点

  • ERAS组住院时间中位数8天,非ERAS组18天,差异有统计学意义(p<0.001)。
  • ERAS组术中失血量中位数600 ml,非ERAS组1050 ml,差异有统计学意义(p<0.001)。
  • ERAS组输血率8.1%、再入院率15%,分别低于非ERAS组的25%和25%(p<0.001和p=0.04)。

核心结论

  • ERAS路径的使用与根治性膀胱切除术患者术中失血量减少和出院加快相关,且不增加再入院率或改变肿瘤学结局。

研究设计与样本

  • 前瞻性收集单中心连续接受根治性膀胱切除术患者的结局。
  • 共453例连续患者接受根治性膀胱切除术,其中393例(87%)采用ERAS。

主要发现

  • ERAS组住院时间中位数8天(四分位距6-13天),非ERAS组18天(四分位距13-25天),p<0.001。
  • ERAS组术中失血量中位数600 ml(四分位距383-969 ml),非ERAS组1050 ml(四分位距900-1575 ml),p<0.001。
  • ERAS组输血率8.1%,非ERAS组25%,卡方检验p<0.001。
  • ERAS组再入院率15%,非ERAS组25%,卡方检验p=0.04。
  • 组织病理学参数(如肿瘤分期、淋巴结计数和切缘状态)及生存结局在ERAS使用与否间无差异(所有p>0.1)。

关键数值与推荐

  • ERAS方案包含26项措施,包括预康复锻炼、同日入院、碳水化合物液体负荷、目标导向术中液体复苏、区域局部麻醉、停止鼻胃管、省略口服肠道准备、避免使用引流管、早期活动、咀嚼口香糖和审计。

临床怎么用

  • 作者结论认为ERAS路径的使用与术中失血量减少和出院加快相关,且不增加再入院率或改变肿瘤学结局。
  • 作者指出应鼓励采用这些路径。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multimodal enhanced recovery after surgery (ERAS) regimens have improved outcomes from colorectal surgery. OBJECTIVE: We report the application of ERAS to patients undergoing radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: Prospective collection of outcomes from consecutive patients undergoing RC at a single institution. INTERVENTION: Twenty-six components including prehabilitation exercise, same day admission, carbohydrate fluid loading, targeted intraoperative fluid resuscitation, regional local anaesthesia, cessation of nasogastric tubes, omitting oral bowel preparation, avoiding drain use, early mobilisation, chewing gum use, and audit. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcomes were length of stay and readmission rate. Secondary outcomes included intraoperative blood loss, transfusion rates, survival, and histopathological findings. RESULTS AND LIMITATIONS: Four hundred and fifty-three consecutive patients underwent RC, including 393 (87%) with ERAS. Length of stay was shorter with ERAS (median [interquartile range]: 8 [6-13] d) than without (18 [13-25], p<0.001). Patients with ERAS had lower blood loss (ERAS: 600 [383-969] ml vs 1050 [900-1575] ml for non-ERAS, p<0.001), lower transfusion rates (ERAS: 8.1% vs 25%, chi-square test, p<0.001), and fewer readmissions (ERAS: 15% vs 25%, chi-square test, p=0.04) than those without. Histopathological parameters (eg, tumour stage, node count, and margin state) and survival outcomes did not differ with ERAS use (all p>0.1). Multivariable analysis revealed ERAS use was (p=0.002) independently associated with length of stay. CONCLUSIONS: The use of ERAS pathways was associated with lower intraoperative blood loss and faster discharge for patients undergoing RC. These changes did not increase readmission rates or alter oncological outcomes. PATIENT SUMMARY: Recovery after major bladder surgery can be improved by using enhanced recovery pathways. Patients managed by these pathways have shorter length of stays, lower blood loss, and lower transfusion rates. Their adoption should be encouraged.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Pang KH, Groves R, Venugopal S, et al. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol. 2017. PMID: 28801130. doi:10.1016/j.eururo.2017.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。